<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03887169</url>
  </required_header>
  <id_info>
    <org_study_id>DC20180338</org_study_id>
    <secondary_id>2018-004140-28</secondary_id>
    <nct_id>NCT03887169</nct_id>
  </id_info>
  <brief_title>Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene.</brief_title>
  <acronym>MetPAP</acronym>
  <official_title>Oral or Enteral Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerance of an oral administration&#xD;
      of methionine in the treatment of pulmonary alveolar proteinosis due to the double mutation&#xD;
      Ala393Thr / Ser567Leu in the MARS gene. This disease is very severe and especially leads to&#xD;
      chronic respiratory insufficiency. There is no curative treatment for this disease. The MARS&#xD;
      gene encodes the methionine tRNA synthetase (MetRS). Mutations in this gene leads to a defect&#xD;
      in MetRS function. In cultured mutated yeast, addition of methionine in culture medium&#xD;
      restores MetRS function. Therefore, the investigators hypothesized that treatment of patients&#xD;
      with methionine could have beneficial effects on the disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary alveolar proteinosis (PAP) is a rare respiratory disorder. Recently, a genetic&#xD;
      cause has been identified for a specific form of PAP predominant on La Reunion Island. This&#xD;
      form is characterized by a multisystem phenotype including PAP, failure to thrive, hepatic&#xD;
      involvement and chronic inflammation. This is a severe disease without any specific treatment&#xD;
      and a high rate of mortality related to end-stage respiratory insufficiency. Two recurrent&#xD;
      mutations were isolated in the MARS gene that encodes the methionine tRNA synthetase (MetRS).&#xD;
      This enzyme catalyzes the ligation of methionine to tRNA and is critical for protein&#xD;
      biosynthesis. Functional studies on mutated yeast show an altered growth and protein&#xD;
      synthesis as compared to control yeast. Addition of methionine in culture medium corrects&#xD;
      these defects. Complementary experiments on human purified MetRS show altered enzymatic&#xD;
      catalytic parameters in mutated forms. Increasing blood concentration of methionine in&#xD;
      patients could correct these parameters and potentially improve patients' phenotype in this&#xD;
      severe disorder where no curative treatment exists.&#xD;
&#xD;
      The main objective of this protocol is to determine the tolerance of a prolonged daily&#xD;
      supplementation of methionine in patients presenting a MARS related PAP. The secondary&#xD;
      objectives are to determine the efficiency of such treatment on respiratory, hepatic,&#xD;
      inflammatory and growth status.&#xD;
&#xD;
      To meet the objectives of the study, enrolled patients will receive daily oral or enteral&#xD;
      methionine administration at increasing doses, under surveillance of plasma levels of&#xD;
      methionine and homocysteine, and possible clinical side effects, until determining the&#xD;
      &quot;ideal&quot; dose for each patient.&#xD;
&#xD;
      Once daily dosage determined for each patient, this dosage will be continued for a total of 2&#xD;
      months with daily clinical monitoring of tolerance and bi-monthly plasma levels surveillance&#xD;
      of methionine and homocysteine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerance Assessment</measure>
    <time_frame>From day 0 to day 75</time_frame>
    <description>No adverse event from day 0 to day 75.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate (cycles /min)</measure>
    <time_frame>At day 0, day 15, day 30, day 45, day 60, day 75</time_frame>
    <description>number of cycles per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen need (L/min)</measure>
    <time_frame>At day 0, day 15, day 30, day 45, day 60, day 75</time_frame>
    <description>Flow in L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory signs of struggle</measure>
    <time_frame>At day 0, day 15, day 30, day 45, day 60, day 75</time_frame>
    <description>Presence or absence of signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung lesions</measure>
    <time_frame>At Day 60</time_frame>
    <description>Lesions appearance on thoracic CT scan, scored form 0 to 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipo-proteinaceous material</measure>
    <time_frame>At each bronchial-alveolar washes during the 2,5 months</time_frame>
    <description>Fluid examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>At Day 15, Day 30, Day 45, Day 60, Day 75</time_frame>
    <description>To evaluate Nutritional status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mid upper arm circumference / head circumference rapport</measure>
    <time_frame>At Day 15, Day 30, Day 45, Day 60, Day 75</time_frame>
    <description>To evaluate Nutritional status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatomegaly</measure>
    <time_frame>At Day 0, Day 15, Day 30, Day 45, Day 60, Day 75</time_frame>
    <description>liver damage evaluate by physician during clinical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cholestasis and hepatic cytolysis</measure>
    <time_frame>At Day 0, Day 15, Day 30, Day 60, Day 75</time_frame>
    <description>liver damage evaluate by biological parameters : ASAT, ALAT, GGT, PAL, Bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatomegaly</measure>
    <time_frame>At Day 0 and Day 60</time_frame>
    <description>liver damage evaluate by echography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C reactive protein</measure>
    <time_frame>At Day 0, Day 30, Day 60</time_frame>
    <description>Biological parameters to evaluate Systemic inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sedimentation rate</measure>
    <time_frame>At Day 0, Day 30, Day 60</time_frame>
    <description>Biological parameters to evaluate Systemic inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin G level</measure>
    <time_frame>At Day 0, Day 30, Day 60</time_frame>
    <description>Biological parameters to evaluate Systemic inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin level</measure>
    <time_frame>At Day 0, Day 30, Day 60</time_frame>
    <description>Biological parameters to evaluate inflammatory anaemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of methionine</measure>
    <time_frame>From Day 0 to Day 75</time_frame>
    <description>Variation of the concentration for each patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of homocysteine</measure>
    <time_frame>From Day 0 to Day 75</time_frame>
    <description>Variation of the concentration for each patient</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Pulmonary Alveolar Proteinosis</condition>
  <condition>Mutation Ala393Thr of the MARS Gene</condition>
  <condition>mutationSer567Leu of the MARS Gene</condition>
  <arm_group>
    <arm_group_label>Methionine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methionine</intervention_name>
    <description>Administration of methionine from D1 to D60</description>
    <arm_group_label>Methionine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin B12, B9, B6, C supplementation</intervention_name>
    <description>In case of hyperhomocysteinemia</description>
    <arm_group_label>Methionine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Methionine/homocysteine Dosage</intervention_name>
    <description>Plasma concentration control of methionine and homocysteine from D0 to D75</description>
    <arm_group_label>Methionine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Thoracic CT scan</intervention_name>
    <description>At D60</description>
    <arm_group_label>Methionine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Abdominal and liver ultrasound.</intervention_name>
    <description>At D60</description>
    <arm_group_label>Methionine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Brain MRI</intervention_name>
    <description>In case of abnormal neurological examination</description>
    <arm_group_label>Methionine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Minor Patient with alveolar proteinosis by double mutation Ala393Thr and SER567LEU of&#xD;
             the MARS gene, genetically proven.&#xD;
&#xD;
          -  Patient in need of prolonged hospitalization in Necker for treatment of&#xD;
             bronchial-alveolar washes in the context of care.&#xD;
&#xD;
          -  Patient for which methionine can be administered orally or by enteral probe&#xD;
             (Nasogastric or gastrostomy probe)&#xD;
&#xD;
          -  Signed Informed consent form by parents / legal guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with alveolar proteinosis by other mutations of the MARS gene&#xD;
&#xD;
          -  Patient with alveolar proteinosis secondary to another etiology or without identified&#xD;
             cause&#xD;
&#xD;
          -  Refusal to participate in the study&#xD;
&#xD;
          -  High blood pressure requiring drug treatment&#xD;
&#xD;
          -  Heart failure&#xD;
&#xD;
          -  Known hypersensitivity to one of the substances used or potentially used in the study:&#xD;
             methionine, vitamins B6, B12, B9 and C&#xD;
&#xD;
          -  Pre-Hypermethioninemia (Methioninemia &gt; + 2 DS of normal for age) whatever the cause&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice HADCHOUEL, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Necker Enfants Malades</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary alveolar proteinosis</keyword>
  <keyword>MARS gene</keyword>
  <keyword>methionine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

